Most Read Articles
02 Jul 2019
New drug applications approved by US FDA as of 16 - 30 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approval. Supplemental approvals may have occurred since the original approval date.
05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).

Adalimumab dose de-escalation possible in most IBD patients

10 Feb 2019
Crohn’s is not the end of the world, as Kathleen Baker’s silver medal proves

Dose de-escalation of adalimumab to 40 mg every 3 weeks is possible in most of the patients with inflammatory bowel disease (IBD), a recent study has shown.

Researchers conducted a retrospective observational study of 56 IBD patients (median age at diagnosis, 25 years; 44.6 percent male) whose adalimumab doses were de-escalated to 40 mg. De-escalation failure was defined as the need for re-escalation, discontinuation of adalimumab treatment, or biochemical, morphological or clinical disease relapse.

Of the patients, 10 had ulcerative colitis while the remaining 46 had Crohn’s disease. The median time on adalimumab medication before de-escalation was 36 months. At the moment of de-escalation, all of the participants were in clinical remission while most (89.3 percent; n=28) were in biochemical remission.

In more than a third of the cases (37.5 percent; n=21), dose de-escalation was a failure, the median time to which was 8.9 years. In this subgroup of patients, 18 (85.7 percent) underwent dose re-escalation due to insufficient disease control. Seventeen of these patients remained on adalimumab medication at the end of the study duration.

In comparison, two-thirds (62.5 percent; n=35) of the participants successfully underwent dose de-escalation, nine of whom eventually stopped adalimumab medication due to deep remission.

Multivariate Cox analysis showed that the only factor significantly correlated with the risk of failure was having an inactive disease on magnetic resonance imaging and/or endoscopy in the year prior to adalimumab de-escalation (hazard ratio, 0.2; 95 percent CI, 0.1–0.8; p=0.02).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
02 Jul 2019
New drug applications approved by US FDA as of 16 - 30 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approval. Supplemental approvals may have occurred since the original approval date.
05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).